Overall, our data showing a reduction of pathogenic tau is consistent with prior studies using a different drug scaffold targeting CSF1R (JNJ-527; edicotinib) in Tg2541 mice18, or using PLX3397 in a different mouse model of tauopathy (TgPS19)17. The gene discussed is MAPT; the disease is tauopathy.